30 reports of this reaction
2.8% of all POTASSIUM NITRATE AND SODIUM FLUORIDE reports
#7 most reported adverse reaction
ORAL MUCOSAL EXFOLIATION is the #7 most commonly reported adverse reaction for POTASSIUM NITRATE AND SODIUM FLUORIDE, manufactured by Haleon US Holdings LLC. There are 30 FDA adverse event reports linking POTASSIUM NITRATE AND SODIUM FLUORIDE to ORAL MUCOSAL EXFOLIATION. This represents approximately 2.8% of all 1,057 adverse event reports for this drug.
Patients taking POTASSIUM NITRATE AND SODIUM FLUORIDE who experience oral mucosal exfoliation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ORAL MUCOSAL EXFOLIATION is a less commonly reported adverse event for POTASSIUM NITRATE AND SODIUM FLUORIDE, but still significant enough to appear in the safety profile.
In addition to oral mucosal exfoliation, the following adverse reactions have been reported for POTASSIUM NITRATE AND SODIUM FLUORIDE:
The following drugs have also been linked to oral mucosal exfoliation in FDA adverse event reports:
ORAL MUCOSAL EXFOLIATION has been reported as an adverse event in 30 FDA reports for POTASSIUM NITRATE AND SODIUM FLUORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ORAL MUCOSAL EXFOLIATION accounts for approximately 2.8% of all adverse event reports for POTASSIUM NITRATE AND SODIUM FLUORIDE, making it a notable side effect.
If you experience oral mucosal exfoliation while taking POTASSIUM NITRATE AND SODIUM FLUORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.